Drugs and Devices

FDA approves first nonhormonal treatment for hot flashes

On June 28, the U.S. Food and Drug Administration (FDA) approved Brisdelle (paroxetine) to treat moderate to severe hot flashes associated with menopause. Brisdelle, which contains the selective serotonin reuptake inhibitor paroxetine mesylate, is currently the only nonhormonal treatment for hot flashes approved by the FDA. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares